Last updated: February 16, 2026
Overview
The drug identified by NDC 00121-0759 is Tymlos (abaloparatide), indicated for the treatment of postmenopausal women at high risk for fracture. This report evaluates its current market landscape, competitive positioning, and pricing trajectory based on recent trends and available data.
Market Context
Tymlos is a self-administered parathyroid hormone analog prescribed for osteoporosis management. Approved by the FDA in 2017, it aims to supplement or replace existing treatments like bisphosphonates. The market's growth hinges upon several factors:
-
Prevalence of osteoporosis: U.S. estimates report approximately 10 million adults with osteoporosis, with postmenopausal women accounting for 80% of cases [1].
-
Market penetration: Tymlos competes with established therapies such as Forteo (teriparatide), with the latter holding an estimated 70% of the anabolic osteoporosis market segment.
-
Physician prescribing trends: Adoption is influenced by insurers' coverage policies, prescribing habits, and patient preference for administration routes.
-
Reimbursement landscape: CMS and private payers provide coverage, but reimbursement levels vary, impacting net revenue potential.
Sales and Revenue Data
Tiymlos’s first-year sales in 2017 were approximately $60 million, with revenues growing to an estimated $250 million by 2022. The growth rate stood at roughly 20% annually, driven by increased prescription volume and expanded insurer coverage.
Pricing Analysis
The wholesale acquisition cost (WAC) for Tymlos is approximately $2,400 per 30-dose carton (~1 month of therapy). After discounts, the average net price ranges between $1,800 and $2,000 per month [2].
Comparison with peers:
| Drug |
Monthly Cost |
Administration Route |
Indication |
| Tymlos (abaloparatide) |
~$2,000 |
Subcutaneous injection |
Osteoporosis, postmenopausal women |
| Forteo (teriparatide) |
~$2,300 |
Subcutaneous injection |
Similar indication |
| Evenity (romosozumab) |
~$2,300 |
Monthly subcutaneous injection |
Osteoporosis with high fracture risk |
Market Projections
Financial forecasts suggest that Tymlos's market will expand modestly over the next five years, contingent upon:
-
Market share gains: A projected 5% annual increase in prescriptions, reaching a 20% share in anabolic osteoporosis market by 2027.
-
Pricing adjustments: Potential for dose consolidation, biosimilar entry, or formulary negotiations could reduce net prices by 10-15% over the next 3-5 years.
-
Regulatory developments: Pending approvals for broader indications or combination therapies could enhance sales.
Competitive Dynamics
The market remains competitive, with established products like Forteo and newer entrants influencing pricing and prescribing:
-
Generic biosimilars: No biosimilar has launched yet, maintaining Tymlos's premium pricing.
-
Market share shifts: Adoption depends on patient preference, efficacy perception, and formulary inclusion.
Key Price Drivers
-
Reimbursement policies and negotiations are primary determinants of final net price.
-
Market expansion through clinical adoption can sustain higher pricing levels.
-
Pricing pressures from biosimilar competition will mainly impact future pricing, potentially decreasing net prices by 10-15% within 3-5 years.
Key Takeaways
-
Tymlos's current retail price is around $2,000 per month, with net revenue roughly $1,800-$2,000 after discounts.
-
Sales are projected to grow at about 20% annually through 2027, reaching approximately $600 million in revenue.
-
The competitive landscape and absence of biosimilars keep pricing relatively stable but suggest possible decreases in the next 3-5 years.
-
Market expansion depends on increased physician adoption and favorable reimbursement policies.
FAQs
1. How does Tymlos compare price-wise to similar osteoporosis treatments?
Tymlos’s monthly net price (~$2,000) aligns with Forteo and Evenity, but it maintains a slight price advantage. Biosimilars are not yet available, limiting pricing pressure.
2. What factors could cause Tymlos's price to decline?
Introduction of biosimilars, formulary negotiations, and patent challenges could lower net prices by 10-15% over the next 3-5 years.
3. How much revenue can Tymlos potentially generate in the next five years?
Assuming the current growth rate and market penetration, revenues could approach $600 million annually by 2027.
4. Who are Tymlos’s main competitors?
Forteo (teriparatide), Evenity (romosozumab), and bisphosphonates like alendronate comprise the main competitive options.
5. How do reimbursement policies impact Tymlos's market price?
Payer negotiations and formulary listings influence net price; favorable coverage facilitates higher prices, while restrictive policies exert downward pressure.
Sources
[1] National Osteoporosis Foundation. (2020). Osteoporosis Facts and Statistics.
[2] IQVIA. (2022). Pricing and Sales Data for Osteoporosis Medications.
